- Home
- QIPT vs MDXH Comparison
QIPT vs MDXH Comparison
Compare QIPT & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QIPT
- MDXH
- Stock Information
- Founded
- QIPT 1993
- MDXH 2003
- Country
- QIPT United States
- MDXH Belgium
- Employees
- QIPT N/A
- MDXH N/A
- Industry
- QIPT
- MDXH
- Sector
- QIPT
- MDXH
- Exchange
- QIPT Nasdaq
- MDXH Nasdaq
- Market Cap
- QIPT 92.2M
- MDXH 84.6M
- IPO Year
- QIPT N/A
- MDXH 2021
- Fundamental
- Price
- QIPT $1.80
- MDXH $2.30
- Analyst Decision
- QIPT Buy
- MDXH Buy
- Analyst Count
- QIPT 2
- MDXH 1
- Target Price
- QIPT $2.85
- MDXH $6.00
- AVG Volume (30 Days)
- QIPT 702.0K
- MDXH 70.5K
- Earning Date
- QIPT 08-13-2025
- MDXH 08-20-2025
- Dividend Yield
- QIPT N/A
- MDXH N/A
- EPS Growth
- QIPT N/A
- MDXH N/A
- EPS
- QIPT N/A
- MDXH N/A
- Revenue
- QIPT $240,848,000.00
- MDXH $94,507,000.00
- Revenue This Year
- QIPT $3.35
- MDXH $23.51
- Revenue Next Year
- QIPT $5.39
- MDXH $17.68
- P/E Ratio
- QIPT N/A
- MDXH N/A
- Revenue Growth
- QIPT N/A
- MDXH 25.46
- 52 Week Low
- QIPT $1.35
- MDXH $1.35
- 52 Week High
- QIPT $4.07
- MDXH $3.50
- Technical
- Relative Strength Index (RSI)
- QIPT 43.89
- MDXH 58.21
- Support Level
- QIPT $1.76
- MDXH $1.90
- Resistance Level
- QIPT $2.18
- MDXH $2.21
- Average True Range (ATR)
- QIPT 0.11
- MDXH 0.12
- MACD
- QIPT -0.01
- MDXH 0.00
- Stochastic Oscillator
- QIPT 8.89
- MDXH 82.35
About QIPT Quipt Home Medical Corp.
Quipt Home Medical Corp provides in-home monitoring equipment, supplies, and services to patients. The Company operates in one business segment, which is the sale and rental of medical equipment and related devices. The company's services consist of Daily and Ambulatory Aides, Power Mobility, INR Self-Testing, Respiratory Equipment Rental, Home ventilation, Oxygen Therapy, and Sleep Apnea and PAP Treatment.
About MDXH MDxHealth SA
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.